469 related articles for article (PubMed ID: 30564246)
1. Therapeutic Targeting of HIV Reservoirs: How to Give T Cells a New Direction.
Yang H; Wallace Z; Dorrell L
Front Immunol; 2018; 9():2861. PubMed ID: 30564246
[TBL] [Abstract][Full Text] [Related]
2. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
[TBL] [Abstract][Full Text] [Related]
3. Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells.
Sung JA; Pickeral J; Liu L; Stanfield-Oakley SA; Lam CY; Garrido C; Pollara J; LaBranche C; Bonsignori M; Moody MA; Yang Y; Parks R; Archin N; Allard B; Kirchherr J; Kuruc JD; Gay CL; Cohen MS; Ochsenbauer C; Soderberg K; Liao HX; Montefiori D; Moore P; Johnson S; Koenig S; Haynes BF; Nordstrom JL; Margolis DM; Ferrari G
J Clin Invest; 2015 Nov; 125(11):4077-90. PubMed ID: 26413868
[TBL] [Abstract][Full Text] [Related]
4. Development of CAR-T cells for long-term eradication and surveillance of HIV-1 reservoir.
Liu B; Zhang W; Zhang H
Curr Opin Virol; 2019 Oct; 38():21-30. PubMed ID: 31132749
[TBL] [Abstract][Full Text] [Related]
5. HIV-1-Specific Chimeric Antigen Receptor T Cells Fail To Recognize and Eliminate the Follicular Dendritic Cell HIV Reservoir
Ollerton MT; Berger EA; Connick E; Burton GF
J Virol; 2020 May; 94(10):. PubMed ID: 32161179
[TBL] [Abstract][Full Text] [Related]
6. Which therapeutic strategy will achieve a cure for HIV-1?
Cillo AR; Mellors JW
Curr Opin Virol; 2016 Jun; 18():14-9. PubMed ID: 26985878
[TBL] [Abstract][Full Text] [Related]
7. Advances in Developing CAR T-Cell Therapy for HIV Cure.
Qi J; Ding C; Jiang X; Gao Y
Front Immunol; 2020; 11():361. PubMed ID: 32210965
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal
Garrido C; Abad-Fernandez M; Tuyishime M; Pollara JJ; Ferrari G; Soriano-Sarabia N; Margolis DM
J Virol; 2018 Jun; 92(12):. PubMed ID: 29593039
[TBL] [Abstract][Full Text] [Related]
9. Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology.
Mylvaganam G; Yanez AG; Maus M; Walker BD
Front Immunol; 2019; 10():2109. PubMed ID: 31552045
[TBL] [Abstract][Full Text] [Related]
10. Current status and future development of anti-HIV chimeric antigen receptor T-cell therapy.
Mao Y; Zhao C; Zheng P; Zhang X; Xu J
Immunotherapy; 2021 Feb; 13(2):177-184. PubMed ID: 33225803
[TBL] [Abstract][Full Text] [Related]
11. Recent advances on anti-HIV chimeric antigen receptor-T-cell treatment to provide sustained HIV remission.
Su H; Mueller A; Goldstein H
Curr Opin HIV AIDS; 2024 Jul; 19(4):169-178. PubMed ID: 38695148
[TBL] [Abstract][Full Text] [Related]
12. Immune Interventions to Eliminate the HIV Reservoir.
Hsu DC; Ananworanich J
Curr Top Microbiol Immunol; 2018; 417():181-210. PubMed ID: 29071472
[TBL] [Abstract][Full Text] [Related]
13. Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells.
Sloan DD; Lam CY; Irrinki A; Liu L; Tsai A; Pace CS; Kaur J; Murry JP; Balakrishnan M; Moore PA; Johnson S; Nordstrom JL; Cihlar T; Koenig S
PLoS Pathog; 2015; 11(11):e1005233. PubMed ID: 26539983
[TBL] [Abstract][Full Text] [Related]
14. Eradication of HIV-1 latent reservoirs through therapeutic vaccination.
Pankrac J; Klein K; Mann JFS
AIDS Res Ther; 2017 Sep; 14(1):45. PubMed ID: 28893280
[TBL] [Abstract][Full Text] [Related]
15. Chimeric antigen receptor T-cell approaches to HIV cure.
Kuhlmann AS; Peterson CW; Kiem HP
Curr Opin HIV AIDS; 2018 Sep; 13(5):446-453. PubMed ID: 29878913
[TBL] [Abstract][Full Text] [Related]
16. The development of immune-modulating compounds to disrupt HIV latency.
Remoli AL; Marsili G; Battistini A; Sgarbanti M
Cytokine Growth Factor Rev; 2012; 23(4-5):159-72. PubMed ID: 22766356
[TBL] [Abstract][Full Text] [Related]
17. Redirection of Cord Blood T Cells and Natural Killer Cells for Elimination of Autologous HIV-1-Infected Target Cells Using Bispecific DART® Molecules.
Pollara J; Edwards RW; Jha S; Lam CK; Liu L; Diedrich G; Nordstrom JL; Huffman T; Pickeral JA; Denny TN; Permar SR; Ferrari G
Front Immunol; 2020; 11():713. PubMed ID: 32373131
[TBL] [Abstract][Full Text] [Related]
18. Bispecific chimeric antigen receptors targeting the CD4 binding site and high-mannose Glycans of gp120 optimized for anti-human immunodeficiency virus potency and breadth with minimal immunogenicity.
Ghanem MH; Bolivar-Wagers S; Dey B; Hajduczki A; Vargas-Inchaustegui DA; Danielson DT; Bundoc V; Liu L; Berger EA
Cytotherapy; 2018 Mar; 20(3):407-419. PubMed ID: 29306566
[TBL] [Abstract][Full Text] [Related]
19. Landscape review of current HIV 'kick and kill' cure research - some kicking, not enough killing.
Thorlund K; Horwitz MS; Fife BT; Lester R; Cameron DW
BMC Infect Dis; 2017 Aug; 17(1):595. PubMed ID: 28851294
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of chimeric antigen receptor T cell therapy in non-human primates infected with SHIV or SIV.
Iwamoto N; Patel B; Song K; Mason R; Bolivar-Wagers S; Bergamaschi C; Pavlakis GN; Berger E; Roederer M
PLoS One; 2021; 16(3):e0248973. PubMed ID: 33752225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]